Rankings
▼
Calendar
IMUX FY 2022 Earnings — Immunic, Inc. Revenue & Financial Results | Market Cap Arena
IMUX
Immunic, Inc.
$135M
FY 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$119M
Net Income
-$120M
EPS (Diluted)
$-3.78
Cash Flow
Operating Cash Flow
-$65M
Free Cash Flow
-$65M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$128M
Total Liabilities
$14M
Stockholders' Equity
$114M
Cash & Equivalents
$107M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$119M
-$92M
-30.4%
Net Income
-$120M
-$93M
-29.5%
← Q4 2021
All Quarters
Q1 2022 →